Cathelicidins - antimicrobal peptides and their role in immuno- pathology



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Cathelicidins are a family of cationic amphipathic antimicrobial polypeptides, which play an important role in innate and adaptive immunity. The knowledge of biological effects of these peptides allows to use them not only as an alternative to common antimicrobial therapies. Cathelicidins may also be used for the re-activation of an immune system that has been suppressed by an infection or inflammation, for modulation of inflammation as lipopolysaccharide-binding drugs, and for the activation of regenerative processes. Besides, examination of cathelicidins may serve to detect individuals prone to infectious diseases, to monitor infectious process control in these patients, and to select efficient therapy.

About the authors

A S Budikhina

Institute of immunology

Email: Budikhina@mail.ru
Institute of immunology

В V Pinegin

Institute of immunology

Institute of immunology

References

  1. Sorensen O.E. The human cathelicidin hCAP-18. Dan. Med. Bull. 2005, v. 52, p. 1-10.
  2. Tjabringa S., Aarbiou J., Ninaber D.K. et al. The Antimicrobial. Peptide LL-37 Activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor G. The Journal of Immunology. 2003, v. 171, p. 6690-6696.
  3. Van Wetering S., Tjabringa S., Hiemstra P. S. Interaction between neurtophil-derived antimicrobial peptides and airway epithelial cells. J. of Leukocyte Biology. 2005, v. 77, p. 444-450.
  4. Johansson J., Gudmundsson G.H., Rottenberg M.R, Berndt K.D. and Agerberth B. Conformation-dependent Antibacterial Activity of the Naturally Occurring Human Peptide LL-37. THE JOURNAL OF BIOLOGICAL CHEMISTRY 1998, v. 273 (6), p. 3718-3724.
  5. Oren Z., Lerman J.C., Gudmundsson GH. et al. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem. J. 1999, v. 341, p. 501-513.
  6. Tjabringa S., Voost J. В., Olthuis D. et al. Host defense effector molecules in mucosal secretions. Immunology and medical. Microbiology. 2005, v. 45, p. 151-158.
  7. Agerberth В., Gunne H, Odeberg J. etal. FALL-37, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc. Natl. Acad. Sci.U.SA. 1995, v. 92, p. 195-199.
  8. Gudmundsson G.H., Agerberth В., Odeberg J. et al. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur. J. Biochem. 1996, v. 238, p. 325-332.
  9. Cowland J.B., Johnsen A.H., Borregaard N. hCAP-18, a cathelin/probactenecin-like protein of human neutrophil specific granules. FEBS Lett. 1995, v. 368, p. 173-176.
  10. Rivas-Santiago В., Hernandez-Pando R, Carranza C, Juarez E., Contreras J.L., Aguilar-Leon D., Torres M. and Sada E. Expression of Cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infection and immunity 2008 (Mar), v. 76 (3), p. 935-941.
  11. Yang D., Chen Q., Schmidt A.P., Anderson G.M. et al. LL-37, the Neutrophil Granule and Epithelial cell-derived Cathelicidin, Utilizes Formyl Peptide Receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. The Journal of Experimental Medicine. 2000 (October 2), v. 192 (7), p. 1069-1074.
  12. Guthmiller J.M., Vargas K.G., Srikantha R., Schomberg L.L., WeistrofferP.L., MCCRAYP.B. andTackB.F. Suscepti-biUties of Oral Bacteria and Yeast to Mammalian Catheli-cidins. ANTIMICROBIAL AGENTS AND CHEMOTHE-RAPY 2001 (Nov), v. 45 (11), p. 3216-3219.
  13. LarrickJ.W., HirataM., Balint RE, Lee J., Zhong J., Wright S.C. Human CAP18: a novel antimicrobial lipopolysaccharide-bin ding protein. Infect. Immun. 1995, v. 63, p. 1291-1297.
  14. Larrick J.W., Hirata M., Zheng H., Zhong J., Bolin D., Cavaillon J.M., Warren H.S., Wright S.C. A novel granu-locyte-derived peptide with lipopolysaccharide-neutr arizing activity. J. Immunol. 1994, v. 152, p. 231-240.
  15. Rosenfeld Y, Papo N, Shai Y, Endotoxin (LPS) neutralization by innate immunity host-defense peptides: peptides' properties and plausible modes of action. J. Biol. Chem. 2006, v. 281, p. 1636-1643.
  16. Zughaier S.M., Shafer W.M., Stephens D.S., Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell. Microbiol. 2005, v. 7, p. 1251-1262.
  17. Dorschner R.A., Pestonjamasp V.K., Tamakuwala S. et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A streptococcus. J. Invest. Dermatol. 2001, v. 117, p. 91-97.
  18. Wang G., Watson K.M., Buckheit R.W Anti-Human Immunodeficiency Virus Type 1 Activities of Antimicrobial Peptides Derived from Human and Bovine Cathelicidins. Antimicrobial agents and chemotherapy. 2008 (Sept.), v. 52 (9), p. 3438-3440.
  19. Bowdish D.M.E., Davidson D.J., Speert D.P. and Hancock R.E.W The Human Cationic Peptide LL-37 Induces Activation of the Extracellular Signal-Regulated Kinase and p38 Kinase Pathways in Primary Human Monocytes. The Journal of Immunology. 2004, v. 172, p. 3758-3765.
  20. Barlow P.G., Li Y, Wilkinson TS., Bowdish D.M.E. et al. The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. J. Leukoc. Biol. 2006. v. 80, p. 509-520.
  21. Bjorstad A., Askarieh G., Brown K.L. et al. The Host Defense Peptide LL-37 Selectively Permeabilizes Apoptotic Leukocytes. Antimicrobial Agents and Chemo-therapy 2009, v. 53, March No. 3. p. 1027-1038.
  22. Zhang Z., Cherryholmes G. and Shively J.E. Neutrophil secondary necrosis is induced by LL-37 derived fromcathe-licidin. Journal of Leukocyte Biology. 2008,v. 84, p. 780-788.
  23. Putsep K, Carlsson G., Boman H.G, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostman: an observation study. Lancet. 2002 (Oct 12), v. 360 (9340), p. 1144-1149.
  24. Ong P. Y, Ohtake T, Brandt С et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 2002, v. 347 (15), p. 1151-1160.
  25. Howell M.D. The role of human beta defensins and cathelicidins in atopic dermatitis. Current Opinion in Allergy & Clinical Immunology. 2007, v. 7 (5), p. 413-417.
  26. Howell M.D., Wollenberg A, Gallo R.L. et al. Cathelicidin deficiency predisposes to eczema herpeticum. J. Allergy Clin. Immunol. 2006, v. 117, p. 836-841.
  27. Zuyderduyn S., Ninaber D.K., Hiemstra PS. and Rabe K.E The antimicrobial peptide LL-37 enhances IL-8release by human airway smooth muscle cells. J. Allergy Clin Immunol. 2006, v. 117, p. 1328-1335.
  28. Chen C.I., Schaller-Bals S., Paul K.P., Wahn U., Bals R. Beta-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J. Cyst. Fibros. 2004 (Mar), v. 3 (1), p. 45-50.
  29. Bals R., Wang X., Wu Z., Freeman T, Bafna V, Zasloff M., Wilson J. M. Human b-Defensin 2 Is a Salt-sensitive Peptide Antibiotic Expressed in Human Lung. J. Clin. Invest. 1998, v. 102, p. 874-880.
  30. Starner T.D., Agerberth В., Gudmundsson G.H. et al. Expression and activity of {beta}-defensins and LL-37 in the developing human lung. J. Immunol. 2005, v. 174 (3), p. 1608-1615.
  31. Bucki R., Byfield F.J. and Janmey PA. Release of the anti-microbial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. Eur Respir J. 2007, v. 29, p. 624-632.
  32. Bucki R., Namiot D. В., Namiot Z., Savage P. B. and Jan-mey PA Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13. J. Antimicrobial Chemotherapy. 2008, v. 62 (2), p. 329-335.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2009



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies